News Focus
News Focus
icon url

NY1972

01/09/26 8:28 AM

#909 RE: jondoeuk #908

>>So the ADR could engage all 4-1BB+ activated lymphocytes
ADR + KO58 skip CTV high lymphocytes. 1st pt. left hosp after 1 day stay, no liver tox
KO58 lowers immune - immune interactions

with KO58, you don't need IL7R to persist
icon url

KIPK

01/11/26 9:37 AM

#911 RE: jondoeuk #908

Joedoeuk
Hoping for failure of others brings same to you & your investment...

Its ...................THE LAW OF RESONANCE...................
Bearish
Bearish
icon url

NY1972

01/18/26 2:23 PM

#913 RE: jondoeuk #908

Do you think chatGPT is hallucnating?
These young smoking females NSCLC with egfr mut. patients are ideal candidates for cetuximab + depletion of 4-1bb high immune cells.

The classic epidemiology is:
EGFR-mutant NSCLC:
more common in
• females
• never-smokers or light smokers
• East Asian ancestry
• younger age

Smoking-related NSCLC:
more common in
• males
• heavy smokers
• KRAS, TP53, NOT EGFR

However, there is a real minority group:
Young female smokers with EGFR-mutant NSCLC
They represent roughly:
~5–15% of EGFR-mutant cases (varies by cohort and ethnicity)
Key features:
Smoking history exists but is usually lighter
Often <10–20 pack-years
Sometimes passive or adolescent exposure
Driver mutation still dominates biology
EGFR addiction remains the main oncogenic program
Immune phenotype is mixed
More inflamed than never-smoker EGFR tumors
Less inflamed than classic smoking KRAS tumors
TMB is intermediate
Higher than pure never-smoker EGFR
Lower than classic smoking NSCLC
PD-1 response still poor
Because EGFR signaling suppresses IFN programs
But slightly better than in pure never-smokers
So they sit in an intermediate immunologic state:
Some exhausted effector pool (from smoking-induced neoantigens)
But strong oncogene-driven immune exclusion

Why this matters for your priming logic
These patients are actually ideal candidates for cetuximab or stress-priming strategies:

EGFR is highly expressed

ADCC can work

NK cells can be recruited

MICA/B can be induced

There is some neoantigen diversity to seed T cells

But regulatory and oncogenic suppression still dominate

So their optimal sequence would be:

Stress / ADCC priming (cetuximab or LD taxane)

Regulatory reset (e.g., 4-1BB^hi depletion)

PD-1 or MICA/B-CAR

They are biologically between:

Never-smoker EGFR (needs priming badly)

Smoking KRAS (needs regulatory reset mainly)

One-sentence summary
Yes — a minority of young female NSCLC patients do have EGFR mutations despite a smoking history, and they form an intermediate immune state where cetuximab priming plus regulatory unlocking may be especially synergistic.